Tislelizumab Clinical Trials

11 recruitingLast updated: June 17, 2026

There are 11 actively recruiting tislelizumab clinical trials across 2 countries. Studies span Phase 2. Top locations include Tianjin, Outside U.S., China, Zibo, Shandong, China, Guangzhou, Guangdong, China. Updated daily from ClinicalTrials.gov.


Tislelizumab Trials at a Glance

11 actively recruiting trials for tislelizumab are listed on ClinicalTrialsFinder across 6 cities in 2 countries. The largest study group is Phase 2 with 11 trials, with the heaviest enrollment activity in Tianjin, Zibo, and Guangzhou. Lead sponsors running tislelizumab studies include Tianjin Medical University Second Hospital, Zibo Municipal Hospital, and Qilu Hospital of Shandong University.

Browse tislelizumab trials by phase

Treatments under study

About Tislelizumab Clinical Trials

Looking for clinical trials for Tislelizumab? There are currently 11 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Tislelizumab trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Tislelizumab clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 111 of 11 trials

Recruiting
Phase 2

Tislelizumab Combined With Anlotinib and Nab-paclitaxel in III Resectable Non-small Cell Lung Cancer : A Prospective, Single-Arm, Phase II Study

NSCLCTislelizumabNab-paclitaxel+1 more
Qilu Hospital of Shandong University34 enrolled1 locationNCT07089199
Recruiting
Phase 2

A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy

Colorectal, CancerMinimal Residual DiseasectDNA+3 more
M.D. Anderson Cancer Center20 enrolled1 locationNCT07136077
Recruiting
Phase 2

Neoadjuvant Chemoradiotherapy Plus Tislelizumab With or Without Probio-M9 in pMMR/MSS Locally Advanced Rectal Cancer

Neoadjuvant TherapyImmunotherapyTislelizumab+3 more
Seventh Medical Center of PLA General Hospital50 enrolled1 locationNCT07458529
Recruiting
Phase 2

Nephron-sparing Treatment of Tislelizumab + Nab-Paclitaxel for Renal Pelvic Cancer

TislelizumabPD-1 InhibitorKidney-sparing+2 more
Tianjin Medical University Second Hospital35 enrolled1 locationNCT07233252
Recruiting
Phase 2

Real World Study of Platinum Containing Dual Drug Chemotherapy Followed by Large Fractionated Radiotherapy Combined withTislelizumab in Stage IIIB/C-IV Non-small Cell Lung Cancer Patient

ChemotherapyNSCLCTislelizumab+1 more
Zibo Municipal Hospital20 enrolled1 locationNCT07198217
Recruiting
Phase 2

Neoadjuvant Tislelizumab + Nab-Paclitaxel Followed by Distal Ureterectomy for Ureteral Cancer

Neoadjuvant TherapyTislelizumabPD-1 Inhibitor+3 more
Tianjin Medical University Second Hospital35 enrolled1 locationNCT07125547
Recruiting
Phase 2

Combination of Concurrent Chemoradiotherapy With Surufatinib and Tislelizumab in Patients With Locally Advanced Non-Small Cell Lung Cancer

Non-small Cell Lung CancerTislelizumabConcurrent Chemoradiotherapy+2 more
Sun Yat-sen University80 enrolled1 locationNCT07086456
Recruiting
Phase 2

Tislelizumab Combined With sCRT in Stage IIIB/C-IV Non-Squamous Non-Small Cell Lung Cancer:A Prospective, Single-Arm, Phase II Study

ChemotherapyNSCLCTislelizumab+1 more
Zibo Municipal Hospital20 enrolled1 locationNCT07085182
Recruiting
Phase 2

Phase II, Single-arm Exploratory Clinical Study of Tislelizumab Combined With Anlotinib in the Treatment of Advanced Pulmonary Pleomorphic Carcinoma

ImmunotherapyTislelizumabPulmonary Pleomorphic Carcinoma
Second Affiliated Hospital of Nanchang University32 enrolled1 locationNCT05375734
Recruiting
Phase 2

Lenvatinib Combined with Tislelizumab and TACE Applied As Neoadjuvant Regimen for the Patients of CNLC Stage IB and IIA Hepatocellular Carcinoma with High-risk Recurrence Factors

Hepatocellular CarcinomaTislelizumabOxaliplatin+3 more
Zhejiang Cancer Hospital35 enrolled1 locationNCT05920863
Recruiting
Phase 2

XELOX +Bev +Tislelizumab for First-line Treatment of MSS/pMMR RAS-mutated mCRC

CapecitabineTislelizumabMetastatic Colorectal Cancer (Mcrc)+5 more
Cancer Institute and Hospital, Chinese Academy of Medical Sciences52 enrolled1 locationNCT05970302